Back to Multiple Sclerosis

NCT07295847

NCT07295847
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are able to understand and sign a consent form agreeing to take part
  • Your overall physical health and body function are considered adequate at the start of the study
  • You are willing and able to stop taking certain medications for a set period of time before the study begins
  • A doctor has reviewed your health and considers you a suitable candidate for the study
  • You are willing to use a reliable form of birth control (or meet other acceptable criteria) during the study

Who may not be able to join:

  • Your Body Mass Index (BMI — a measure of body weight relative to height) is below 18 or above 35 at the start of the study
  • You have previously received a type of treatment called CAR T-cell therapy
  • You are unable or unwilling to stay within roughly 2 hours' travel of the study clinic for the first 28 days after receiving the study treatment
  • You have ever had a bone marrow or organ transplant, or are currently on a waiting list for one
  • You have taken part in another clinical trial or received an experimental drug too recently before screening
  • You have certain heart conditions that a doctor determines could make it unsafe for you to participate (confirm with trial site)
  • You need extra oxygen while resting (not including oxygen used at night for sleep apnoea) or require a breathing machine
  • You have high blood pressure that is not well controlled (above 160/100 mmHg) or are experiencing symptoms caused by high blood pressure
  • You have a disease affecting your brain or nervous system that a doctor believes could put you at risk
  • You have another active autoimmune or inflammatory condition, although some may be considered after discussion with the medical team
  • You have had significant bleeding or an active bleeding problem in the 90 days before the study screening
  • You have a history of cancer or are currently being treated for a previous cancer, although some types may be considered as exceptions
  • You have a known inherited condition that affects how your immune system works
  • You have an active infection (viral, bacterial, or fungal) or have needed antibiotic/antiviral/antifungal treatment in the 4 weeks before screening
  • You have tested positive for HIV
  • You have an active hepatitis infection
  • You have active syphilis or have tested positive for the bacteria that causes syphilis
  • You have received a live vaccine (a vaccine made with a weakened live virus or bacteria) within 4 weeks before certain study procedures
  • Your vaccinations are not up to date according to the guidelines recommended for people with weakened immune systems in your area
  • You have a known serious allergy or dangerous reaction to the study drug (AZD0120) or any of its ingredients, including a substance called dimethyl sulfoxide
  • You have a known allergy or serious reaction to two medicines called fludarabine or cyclophosphamide, which are used as part of the treatment process
  • You have recently had major surgery or have surgery planned during the time you would be in the study
  • You are currently pregnant, breastfeeding, or planning to become pregnant during the study or within 1 year of receiving the study treatment
  • You are planning to father a child during the study or within 1 year of receiving the study treatment
  • There is any other reason — in the doctor's opinion — why taking part would not be in your best interest or could affect your ability to safely receive or tolerate the treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
9 January 2026
Est. completion
22 February 2028

Where this trial is recruiting

🇦🇺 Australia 🇩🇪 Germany 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov